LD vehicle-GNP

BIOLOGICAL2 trials

Sponsors

Gylden Pharma Ltd

Conditions

COVID-19CoronavirusDengueSARS-CoV-2 Infection

Phase 1

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus

CompletedNCT04935801

Gylden Pharma LtdDengue

Start: 2021-08-02End: 2022-09-15Updated: 2022-12-05

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

CompletedNCT05113862

Gylden Pharma LtdCoronavirus, COVID-19, SARS-CoV-2 Infection

Start: 2022-01-10End: 2022-09-15Updated: 2025-02-12

Related Papers

A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.

2025-04-072 citations

Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.

2023-12-2024 citations